AstraZeneca PLC
Bear Case (25th pct.)
38.7% vs price
Base Case (Median)
50.8% vs price
Bull Case (75th pct.)
78.8% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $310.10 | 82.8% | High (40%) |
| PE Comparable | $296.55 | 74.8% | Medium (25%) |
| Growth Trajectory DCF | $447.26 | 163.7% | Medium (20%) |
| Graham Number | $137.19 | -19.1% | Medium (40%) |
| EV/EBITDA | $255.86 | 50.8% | Medium (20%) |
| EV/FCF | $225.55 | 33.0% | Medium (20%) |
| Earnings Power Value | $245.17 | 44.5% | Medium (50%) |
Based on 7 out of 8 methods, AZN appears undervalued at the current price of $169.64. The base case fair value of $255.86 implies 50.8% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.